Seroquel vs Abilify
Seroquel (quetiapine) and Abilify (aripiprazole) are both second-generation (atypical) antipsychotics used as adjunctive treatments for depression, bipolar disorder, and schizophrenia. Despite belonging to the same broad drug class, they have strikingly different pharmacological profiles that make them feel like very different medications in clinical practice — particularly with respect to sedation, weight gain, and activation.
Quick Comparison
| Feature | Quetiapine (Seroquel) | Aripiprazole (Abilify) |
|---|---|---|
| Drug Class | Atypical antipsychotic (dopamine/serotonin antagonist) | Atypical antipsychotic (partial dopamine agonist) |
| Generic Name | Quetiapine | Aripiprazole |
| Brand Name | Seroquel, Seroquel XR | Abilify, Abilify MyCite, Abilify Maintena (injectable) |
| Approved For | Schizophrenia, bipolar I (mania, depression, maintenance), MDD adjunct, bipolar disorder in children/adolescents | Schizophrenia, bipolar I, MDD adjunct, irritability in autism, Tourette's disorder, agitation in schizophrenia/bipolar |
| Available as Generic | Yes | Yes |
| Key Advantage | Highly sedating (useful when insomnia is a problem); strong mood stabilization in bipolar | Low weight gain risk; activating (helps fatigue); unique partial dopamine agonist mechanism; monthly injectable available |
| Main Drawback | Significant weight gain and metabolic effects; sedation limits daytime use; QTc prolongation risk | Activating — can worsen insomnia and anxiety; akathisia (restlessness) is a notable side effect |
How They're Similar
Both quetiapine and aripiprazole are atypical antipsychotics approved for schizophrenia, bipolar disorder, and as adjuncts to antidepressants in MDD. Both carry class-wide FDA black box warnings: an increased risk of death in elderly patients with dementia-related psychosis, and an increased risk of suicidal thinking and behavior in children, adolescents, and young adults. Neither should be used for dementia-related behavioral issues.
Long-term use of either drug carries a risk of tardive dyskinesia — involuntary movements that may become permanent. Both require monitoring of metabolic parameters (fasting glucose, lipids, weight) during treatment.
Key Differences
Mechanism: The most important mechanistic distinction is that aripiprazole is a partial dopamine agonist — it partially activates D2 receptors rather than simply blocking them. This makes it unique among antipsychotics and contributes to its activating (rather than sedating) profile and its relatively low rates of weight gain and prolactin elevation. Quetiapine is a multi-receptor antagonist, blocking D2, serotonin 5-HT2A, histamine H1, and alpha-1 adrenergic receptors — the H1 antagonism drives its significant sedation.
Sedation: Quetiapine is one of the most sedating antipsychotics and is widely used off-label as a sleep aid at low doses — a use that has drawn significant scrutiny given the metabolic risks even at low doses. Aripiprazole is among the least sedating atypical antipsychotics and may actually be activating or cause insomnia in some patients.
Weight and metabolic effects: Quetiapine is associated with clinically significant weight gain and worsening of metabolic parameters including blood glucose and lipids. Aripiprazole has one of the lowest weight gain profiles of any atypical antipsychotic — often considered weight neutral or near-neutral.
Unique indications: Aripiprazole is FDA-approved for irritability associated with autism spectrum disorder (ages 6–17) and Tourette's disorder — indications quetiapine does not hold. Quetiapine has a specific indication for bipolar depression, which is clinically valuable and supported by robust trial data.
Quetiapine: Strengths & Weaknesses
Strengths: Powerful sedation is useful when insomnia, agitation, or mania require rapid calming. Strong evidence base for bipolar depression. Very well tolerated from a neurological standpoint (lower EPS risk than older antipsychotics). Generics are cheap and widely available.
Weaknesses: Weight gain and metabolic syndrome risk are significant concerns with long-term use. Sedation limits use to evening dosing in most patients. Risk of QTc prolongation requires cardiac monitoring. Off-label use as a sleep aid raises safety/benefit questions at even low doses.
Aripiprazole: Strengths & Weaknesses
Strengths: Low weight gain risk, activating effects helpful for fatigue-predominant presentations, low prolactin elevation, broad indications including autism and Tourette's, long-acting injectable option (Abilify Maintena) for adherence challenges, and embedded sensor formulation (Abilify MyCite) for adherence monitoring.
Weaknesses: Akathisia (a distressing sensation of inner restlessness) is a notable and often underrecognized side effect. The activating profile can worsen anxiety and insomnia. Less useful in acute agitation requiring rapid sedation.
Frequently Asked Questions
Is Seroquel used as a sleep aid?
Quetiapine is very commonly prescribed off-label for insomnia due to its H1 antihistamine effects. However, this practice is controversial — even at low doses, quetiapine carries metabolic risks. The FDA has not approved it for insomnia, and most sleep medicine guidelines recommend against this use except in patients already taking quetiapine for an approved indication.
Which causes more weight gain?
Quetiapine is associated with substantially more weight gain than aripiprazole. Aripiprazole is one of the most weight-neutral atypical antipsychotics. For patients where weight is a primary concern, this difference is clinically meaningful.
What is akathisia and which drug causes it more?
Akathisia is a subjective feeling of inner restlessness — an uncomfortable urge to move that is distinct from physical anxiety. It occurs with both drugs but is more commonly associated with aripiprazole, partly because its activating mechanism can manifest this way. It can be severe enough to require a dose reduction or medication change.
Can these drugs be used together?
In specialized psychiatric practice, atypical antipsychotics are occasionally combined under careful supervision for refractory cases. This is not a routine approach and requires specialist oversight given the additive risk of metabolic side effects and QTc prolongation.
⚠ This comparison is for informational purposes only. Never start, stop, or switch medications without guidance from a licensed healthcare provider. Individual responses to medication vary significantly.